SANTA MONICA, Calif., April 18 AidaPharmaceuticals, Inc. (OTC Bulletin Board: AIDA) (hereinafter referred to as"Aida") today announced that it is developing a potential cancer drug thatseeks to trigger cell death in certain types of cancer. Vasostatin-Apo2L, apre-clinical product being developed by Aida's Shanghai Qiaer subsidiary, is arecombinant fusion protein that integrates the function of extracted fragmentsof Vasostatin, an inhibitor of angiogenesis and tumor growth, with thefunction of Rh-Apo2L, which induces the apoptosis of cancer cells. It hasshown positive results in the lab. Aida's researchers believe that theintegration of Vasostatin-Apo2L will have higher efficacy in certain cancertreatments than currently prescribed methods.
Aida estimates that Vasostatin will have a target market of 80,000-100,000patients per year after it is successfully brought to market and this willcontribute significantly to Aida's revenue.
Vasostatin-Apo2L is developed by the same research team that createdRh-Apo2L. Rh-Apo2L has successfully completed its Phase 2 clinical testing andis going to file application with the PRC government's State Food and DrugAdministration to start the Phase III trials. The development ofVasostatin-Apo2L will benefit strongly from the experience garnered in theresearch, manufacturing and distribution of Rh-Apo2L.
About Aida Pharmaceuticals
Aida Pharmaceuticals is a product-focused pharmaceuticals company engagedin the formulation, clinical testing, registration, manufacture, sales andmarketing of advanced pharmaceutical and genetic products in mainland China.The Company's mission is to discover, develop and market meaningful newtherapies that improve human health. Aida Pharmaceuticals, in operation sinceMarch 1999, is headquartered in Hangzhou, China with manufacturing,distribution and sales points throughout mainland China. Aida is GMPcertified in China and ISO9002 certified for quality assurance and ISO14000certified for ecologically-friendly practices.
For additional information, please visit http://en.aidapharma.com.
Safe Harbor Statement Under The Private Securities Litigation Reform Actof 1995: Except for historical information contained herein, the statementsin this news release are forward-looking statements that are made pursuant tothe safe harbor provisions of the Private Securities Litigation Reform Act of1995. Forward-looking statements involve known and unknown risks anduncertainties, which may cause a company's actual results, performance andachievement in the future to differ materially from forecasted results,performance, and achievement. These risks and uncertainties are described inthe Company's periodic filings with the Securities and Exchange Commission.The Company undertakes no obligation to publicly release the result of anyrevisions to these forward-looking statements that may be made to reflectevents or circumstances after the date hereof, or to reflect the occurrence ofunanticipated events or changes in the Company's plans or expectations.
SOURCE Aida Pharmaceuticals, Inc.